CAR T-cell therapy in Lymphocytic Leukemia - A Pipeline Analysis Report
Published: Jun 2018 | Pages: 138 | SKU: IRTNTR23184 |
Overview of the drug development pipeline for CAR T-cell therapy in Lymphocytic Leukemia
Leukemia is the cancer of blood cells, that degenerates the death of damaged cells in comparison to normal cells. Leukemia is diversified into myeloid leukemia, occurring in the myeloid cells, or lymphocytic leukemia, occurring in the bone marrow. Lymphocytic leukemia occurs during the early formation time of the lymphocytes in the bone marrow. It is further segregated into chronic lymphocytic leukemia (CLL) or acute lymphocytic leukemia (ALL). CLL progresses over a period of months or years, whereas ALL progresses quickly and becomes fatal if left untreated. This disease inflicts those with higher genetic chances of developing CLL or ALL. Technavio’s market research analysts have predicted that with the increased effectiveness against cancer cells, various CAR T-cell therapies are being developed for both forms of leukemia. This pipeline analysis identifies that the most common target for CAR T-cell therapies for leukemia is CD19.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the Phase I and Phase I/II drug development stage. Our market research analysts have also identified that these molecule segments are followed by the pre-clinical drug development phase. The pipeline landscape in the pipeline analysis report also mentions the same percentage of drug development molecules that are in phase II and phase III drug development stages.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of CAR T-cell therapy in Lymphocytic Leukemia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
- Novartis
- Cellectis
- Immune Cell
Therapeutic assessment of the drug development pipeline for CAR T-cell therapy in Lymphocytic Leukemia by route of administration
- Intravenous
The intravenous route of administration (ROA) involves the administration of drug substances directly into a vein. It has been observed that the majority of total therapeutics for lymphocytic leukemia are being developed for intravenous administration.
Therapeutic assessment of the drug development pipeline for CAR T-cell therapy in Lymphocytic Leukemia by therapies employed
- Monotherapy
- Monotherapy + combination therapy
According to this pipeline analysis report, majority of the therapies being employed for lymphocytic leukemia are being developed as monotherapy. Monotherapy consists of the use of a single drug to treat a particular disorder.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
- US
- Europe
- China
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX
- List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
PURCHASE FULL REPORT OF
market
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
- Off-the-shelf research reports
- Reports can be tailored to meet the customer's needs
- Trusted by more than 100 fortune 500 organizations
- Information about the market's key drivers, trends, and challenges
- Parent market analysis
- Every week, 50,000 people visit our subscription platform
- Detailed vendors report with competitive landscape
- Covid-19 impact and recovery analysis
- Data on revenue-generating market segments
- Details on the market shares of various regions
- Five-force market analysis